Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

Summary

The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of spCART-269 in treatment of relapsed or refractory multiple myeloma patients.

Timeline

Start

2018-07-01

Primary completion

2022-07-01

Completion

2022-12-01

Drugs

Indications